Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis.
Pulmonary fibrosis is a chronic progressive disease with limited therapeutic options and inflammatory cytokines play important roles in the pathogenesis of pulmonary fibrosis. Here, we investigated the changes of TGF-β1, IL-8, and IL-17 in the serum of bleomycin-A5-induced rats model of pulmonary fibrosis. 120 healthy male Wistar rats were randomly divided into three groups, the control group (n = 30), the model group (n = 45) and the dexamethasone (DEX) group (n = 45). The rats of both model group and DEX group were injected with Bleomycin-A5 (5 mg/kg) through tracheofistulization to induce pulmonary fibrosis, while the rats of the control group were injected with equivalent physiological saline. After operation, DEX (4 mg/kg) was given to the DEX group rats intraperitoneally once a day. Equivalent saline was administered to rats of both the control group and the model group. On the 1st, 14th, and 28th day after operation, pathological changes of the lung tissues, and the levels of serum IL-8, TGF-β1, and IL-17 were measured. The concentrations of serum TGF-β1, IL-8, and IL-17 were significantly increased after bleomycin-A5 treatment, especially on the 14th day (p < .01). There was no significant difference between model group and DEX group in the serum level of TGF-β1 and IL-8, but DEX treatment significantly reduce serum IL-17 level (p < .01). DEX protect bleomycin-A5-induced pulmonary fibrosis in rats through reduced the level of IL-17 in serum.